{"schemaVersion":"wpf-profile-export-v1","exportedAt":"2026-09-18T15:17:30.947Z","profile":{"slug":"lanreotide","name":"Lanreotide","aliases":[],"category":"Somatostatin analog"},"synthesis":{"mechanism":"Lanreotide is a synthetic cyclic octapeptide somatostatin analog with high affinity particularly for somatostatin receptor subtypes 2 and 5. Receptor activation suppresses growth-hormone secretion and multiple gastroenteropancreatic hormones and can exert antiproliferative effects in selected somatostatin-receptor-expressing neuroendocrine tumors. Depot and Autogel formulations provide prolonged exposure; approved indications and administration requirements vary by product and jurisdiction.","evidence":"The governed 25-source corpus includes CLARINET and its extension, ELECT, PAOLA, LANTERN, PRIMARYS, acromegaly comparisons and formulation studies, pharmacokinetic/pharmacodynamic analyses, neuroendocrine-tumor systematic review and patient-reported outcomes, polycystic liver/kidney randomized research, and postmarketing pharmacovigilance. Source identities, metadata, DOI/PMID links, lanreotide relevance, active status, and duplication were verified against PubMed. Evidence lanes distinguish randomized, observational, systematic-review, PK/PD, and spontaneous-report analyses; ratings remain provisional pending Owner review.","safety":"Interpretation depends on tumor site, grade, receptor expression, prior therapy, secretory status, acromegaly control criteria, formulation, injection technique, and follow-up. Gallbladder effects, glucose dysregulation, bradycardia, thyroid changes, gastrointestinal effects, injection-site problems, and drug interactions require clinical context. Open-label extensions and observational cohorts are susceptible to selection and attrition; spontaneous-report databases have reporting bias and no reliable denominator. Current official labeling—not this profile—controls use and monitoring.","observationalBoundary":"Randomized evidence supports disease-control roles in acromegaly and selected gastroenteropancreatic neuroendocrine tumors, with indication-specific outcomes such as biochemical control, tumor progression, symptoms, rescue-medication use, and quality of life. Research in polycystic liver and kidney disease is kept as a separate, non-label evidence lane. Comparative studies with octreotide and pasireotide inform tolerability, convenience, and biochemical control but do not make products interchangeable. Postmarketing signal analyses generate hypotheses and cannot establish incidence or causality.","openQuestions":"Which biomarkers best predict antiproliferative and symptom response by tumor type and grade? What is the optimal sequence or combination with surgery, radionuclide therapy, targeted agents, and other somatostatin analogs? How do extended dosing intervals affect exposure, disease control, adherence, and quality of life? Which long-term metabolic, biliary, cardiovascular, and injection-site harms are underestimated in trials? Can head-to-head pragmatic trials clarify comparative effectiveness? Which polycystic-liver findings are clinically meaningful and transferable without conflating investigational and approved uses?"},"completion":{"version":"wpf-profile-v1.0","complete":false,"checks":[{"key":"overview","passed":true,"actual":495,"required":100,"severity":"blocking"},{"key":"evidence_summary","passed":true,"actual":631,"required":100,"severity":"blocking"},{"key":"safety_summary","passed":true,"actual":591,"required":100,"severity":"blocking"},{"key":"archive_boundary","passed":true,"actual":602,"required":75,"severity":"blocking"},{"key":"open_questions","passed":true,"actual":626,"required":75,"severity":"blocking"},{"key":"verified_sources","passed":true,"actual":25,"required":25,"severity":"blocking"},{"key":"reviewed_sources","passed":false,"actual":0,"required":1,"severity":"blocking"},{"key":"chemistry","passed":true,"actual":true,"required":true,"severity":"blocking"},{"key":"regulatory_context","passed":true,"actual":2,"required":2,"severity":"blocking"},{"key":"claims","passed":false,"actual":0,"required":1,"severity":"blocking"},{"key":"claim_traceability","passed":true,"actual":0,"required":0,"severity":"blocking"},{"key":"regulatory_freshness","passed":true,"actual":0,"required":0,"severity":"warning"}],"failures":["reviewed_sources","claims"]},"chemistry":{"id":"94ee9ad622eafc56b7db5dbf38458cbc","peptideId":"3008f1ff-3f15-452c-808d-b8223f27ee12","molecularFormula":"C54H69N11O10S2","molecularWeight":1096.3,"aminoAcidSequence":"[D-2-naphthylalanine]-Cys-Tyr-[D-Trp]-Lys-Val-Cys-Thr-NH2; Cys2-Cys7 disulfide","smiles":"C[C@H]([C@@H](C(=O)N)NC(=O)[C@@H]1CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)C(C)C)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)N)O","inchi":"InChI=1S/C54H69N11O10S2/c1-29(2)45-54(75)63-44(53(74)65-46(30(3)66)47(57)68)28-77-76-27-43(62-48(69)38(56)23-32-15-18-33-10-4-5-11-34(33)22-32)52(73)60-41(24-31-16-19-36(67)20-17-31)50(71)61-42(25-35-26-58-39-13-7-6-12-37(35)39)51(72)59-40(49(70)64-45)14-8-9-21-55/h4-7,10-13,15-20,22,26,29-30,38,40-46,58,66-67H,8-9,14,21,23-25,27-28,55-56H2,1-3H3,(H2,57,68)(H,59,72)(H,60,73)(H,61,71)(H,62,69)(H,63,75)(H,64,70)(H,65,74)/t30-,38-,40+,41+,42-,43+,44+,45+,46+/m1/s1","inchikey":"PUDHBTGHUJUUFI-SCTWWAJVSA-N","structureImageUrl":"https://pubchem.ncbi.nlm.nih.gov/rest/pug/compound/cid/6918011/PNG","createdAt":"2026-09-09T22:24:51.058Z","updatedAt":"2026-09-09T22:24:51.058Z"},"evidence":[{"id":"805cd2b8e51f023373082f027d136d5e","peptideId":"3008f1ff-3f15-452c-808d-b8223f27ee12","title":"Comparative analysis of adverse event profiles of lanreotide and octreotide in somatostatin-responsive endocrine and neoplastic diseases.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/40437077/","evidenceTier":"observational","summary":"Lanreotide and Octreotide are used to treat various endocrine and neoplastic diseases.","authors":"Le Wang, Shenglin Chen, Mengying Wu, Lijuan Zhou","publishingOrg":"Scientific reports","publicationYear":2025,"doi":"10.1038/s41598-025-03850-7","pubmedId":"40437077","jurisdiction":null,"dateAccessed":"2026-09-09T22:20:33.332Z","editorialNotes":"Identity and metadata verified against the NCBI PubMed record; evidence strength is provisional pending Owner review.","sourceType":"peer_reviewed_research","claimSupported":"Directly informs the Lanreotide evidence profile within the limits of its study design.","supportNature":"Direct or contextual support; no extrapolation beyond the source design.","qualification":"Publication identity verified; full-text risk-of-bias and applicability require governed review.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-automation-profile-corpus-v1","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1038/s41598-025-03850-7","sourceIdentityId":"e35e292d7505c9de10cc7471505b768a","sourceStatus":"active","sourceContentHash":"13f84e47c349167578a8ae7e071e3d441f155ad186fe6be083715bb3282ec7c3","sourceVersion":1,"retrievedAt":"2026-09-09T22:20:33.332Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"pubmed:40437077","evidenceLane":"human_observational","extractionPayload":{"outcomes":"No claim-level outcome imported without full-text adjudication.","limitations":"Source identity and relevance verified; detailed risk-of-bias and applicability remain for profile-level Owner review.","studyDesign":"observational, comparative, monitoring, or contextual human study","sourceStrength":{"grade":"B","score":75,"version":"WPF-ESR-1.0","dimensions":{"identity":100,"directness":85,"replication":70,"studyDesign":75,"regulatoryRelevance":60},"provisional":true},"populationOrModel":"See source abstract and full text; identity verified at PubMed."},"provenancePayload":{"doi":"10.1038/s41598-025-03850-7","locator":"https://pubmed.ncbi.nlm.nih.gov/40437077/","provider":"pubmed","sourceRole":"published_literature","retrievedAt":"2026-09-09T21:45:00Z","rawPayloadHash":"13f84e47c349167578a8ae7e071e3d441f155ad186fe6be083715bb3282ec7c3","sourceRoleBasis":"provider_authoritative_index","providerRecordId":"40437077","rawPayloadReference":"pubmed:40437077"},"validationGates":{"gates":[{"id":"G1","passed":true,"required":true,"reasonCodes":[]},{"id":"G2","passed":true,"required":true,"reasonCodes":[]},{"id":"G3","passed":true,"required":true,"reasonCodes":[]},{"id":"G4","passed":true,"required":true,"reasonCodes":[]},{"id":"G5","passed":true,"required":true,"reasonCodes":[]},{"id":"G6","passed":true,"required":true,"reasonCodes":[]},{"id":"G7","passed":true,"required":true,"reasonCodes":[]},{"id":"G8","passed":true,"required":true,"reasonCodes":[]}],"sourceRole":"published_literature","disposition":"promote_internal","reasonCodes":[],"catastrophic":false,"ownerAuthorized":false,"sourceRoleBasis":"provider_authoritative_index","citationSourceType":"peer_reviewed_research","admitsExactPublishedEvidence":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-09T22:20:33.332Z","updatedAt":"2026-09-09T22:31:57.546Z"},{"id":"ff277b2921ca540a11142f34d259d639","peptideId":"3008f1ff-3f15-452c-808d-b8223f27ee12","title":"Safety profile of lanreotide: a retrospective post-marketing pharmacovigilance study based on the real-world data from FAERS database.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/40468101/","evidenceTier":"observational","summary":"Lanreotide, a class of synthetic somatostatin analogs (SSAs), is the recommended first-line treatment for neuroendocrine tumors (NETs) and acromegaly.","authors":"Yankun Li, Yue Han, Peng Gao","publishingOrg":"Endocrine","publicationYear":2025,"doi":"10.1007/s12020-025-04301-z","pubmedId":"40468101","jurisdiction":null,"dateAccessed":"2026-09-09T22:20:33.332Z","editorialNotes":"Identity and metadata verified against the NCBI PubMed record; evidence strength is provisional pending Owner review.","sourceType":"peer_reviewed_research","claimSupported":"Directly informs the Lanreotide evidence profile within the limits of its study design.","supportNature":"Direct or contextual support; no extrapolation beyond the source design.","qualification":"Publication identity verified; full-text risk-of-bias and applicability require governed review.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-automation-profile-corpus-v1","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1007/s12020-025-04301-z","sourceIdentityId":"2a63653b7ce2ed9f30f2819e54705928","sourceStatus":"active","sourceContentHash":"a8c629473765bbde71b4ee5be62bce203639c756f70e8c779633e2719b6e04b6","sourceVersion":1,"retrievedAt":"2026-09-09T22:20:33.332Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"pubmed:40468101","evidenceLane":"human_observational","extractionPayload":{"outcomes":"No claim-level outcome imported without full-text adjudication.","limitations":"Source identity and relevance verified; detailed risk-of-bias and applicability remain for profile-level Owner review.","studyDesign":"observational, comparative, monitoring, or contextual human study","sourceStrength":{"grade":"B","score":75,"version":"WPF-ESR-1.0","dimensions":{"identity":100,"directness":85,"replication":70,"studyDesign":75,"regulatoryRelevance":60},"provisional":true},"populationOrModel":"See source abstract and full text; identity verified at PubMed."},"provenancePayload":{"doi":"10.1007/s12020-025-04301-z","locator":"https://pubmed.ncbi.nlm.nih.gov/40468101/","provider":"pubmed","sourceRole":"published_literature","retrievedAt":"2026-09-09T21:45:00Z","rawPayloadHash":"a8c629473765bbde71b4ee5be62bce203639c756f70e8c779633e2719b6e04b6","sourceRoleBasis":"provider_authoritative_index","providerRecordId":"40468101","rawPayloadReference":"pubmed:40468101"},"validationGates":{"gates":[{"id":"G1","passed":true,"required":true,"reasonCodes":[]},{"id":"G2","passed":true,"required":true,"reasonCodes":[]},{"id":"G3","passed":true,"required":true,"reasonCodes":[]},{"id":"G4","passed":true,"required":true,"reasonCodes":[]},{"id":"G5","passed":true,"required":true,"reasonCodes":[]},{"id":"G6","passed":true,"required":true,"reasonCodes":[]},{"id":"G7","passed":true,"required":true,"reasonCodes":[]},{"id":"G8","passed":true,"required":true,"reasonCodes":[]}],"sourceRole":"published_literature","disposition":"promote_internal","reasonCodes":[],"catastrophic":false,"ownerAuthorized":false,"sourceRoleBasis":"provider_authoritative_index","citationSourceType":"peer_reviewed_research","admitsExactPublishedEvidence":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-09T22:20:33.332Z","updatedAt":"2026-09-09T22:31:57.546Z"},{"id":"5486670fd11ba086985c568ce5c3c93d","peptideId":"3008f1ff-3f15-452c-808d-b8223f27ee12","title":"A Randomized Trial Evaluating Patient Experience and Preference Between Octreotide Long-Acting Release and Lanreotide for Treatment of Well-Differentiated Neuroendocrine Tumors.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/35724357/","evidenceTier":"phase_1_2","summary":"Somatostatin analogs octreotide long-acting release (octLAR) and lanreotide are equally acceptable in National Comprehensive Cancer Network guidelines for neuroendocrine tumors (NETs).","authors":"Nitya Raj, Elizabeth Cruz, Sarah O'Shaughnessy, Claudia Calderon, Joanne F Chou, Marinela Capanu, Olivia Heffernan, April DeMore, Sippy Punn, Tiffany Le, Haley Hauser, Leonard Saltz","publishingOrg":"JCO oncology practice","publicationYear":2022,"doi":"10.1200/op.22.00055","pubmedId":"35724357","jurisdiction":null,"dateAccessed":"2026-09-09T22:20:33.332Z","editorialNotes":"Identity and metadata verified against the NCBI PubMed record; evidence strength is provisional pending Owner review.","sourceType":"peer_reviewed_research","claimSupported":"Directly informs the Lanreotide evidence profile within the limits of its study design.","supportNature":"Direct or contextual support; no extrapolation beyond the source design.","qualification":"Publication identity verified; full-text risk-of-bias and applicability require governed review.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-automation-profile-corpus-v1","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1200/op.22.00055","sourceIdentityId":"53df0dda21e65397125e585c8ca0cc1b","sourceStatus":"active","sourceContentHash":"20409fd811f89e3b1afcd36f1cc76329a9dadfc91a08c883f3c96900d29101ad","sourceVersion":1,"retrievedAt":"2026-09-09T22:20:33.332Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"pubmed:35724357","evidenceLane":"human_interventional","extractionPayload":{"outcomes":"No claim-level outcome imported without full-text adjudication.","limitations":"Source identity and relevance verified; detailed risk-of-bias and applicability remain for profile-level Owner review.","studyDesign":"randomized or prospective clinical study","sourceStrength":{"grade":"B","score":80,"version":"WPF-ESR-1.0","dimensions":{"identity":100,"directness":85,"replication":70,"studyDesign":80,"regulatoryRelevance":60},"provisional":true},"populationOrModel":"See source abstract and full text; identity verified at PubMed."},"provenancePayload":{"doi":"10.1200/OP.22.00055","locator":"https://pubmed.ncbi.nlm.nih.gov/35724357/","provider":"pubmed","sourceRole":"published_literature","retrievedAt":"2026-09-09T21:45:00Z","rawPayloadHash":"20409fd811f89e3b1afcd36f1cc76329a9dadfc91a08c883f3c96900d29101ad","sourceRoleBasis":"provider_authoritative_index","providerRecordId":"35724357","rawPayloadReference":"pubmed:35724357"},"validationGates":{"gates":[{"id":"G1","passed":true,"required":true,"reasonCodes":[]},{"id":"G2","passed":true,"required":true,"reasonCodes":[]},{"id":"G3","passed":true,"required":true,"reasonCodes":[]},{"id":"G4","passed":true,"required":true,"reasonCodes":[]},{"id":"G5","passed":true,"required":true,"reasonCodes":[]},{"id":"G6","passed":true,"required":true,"reasonCodes":[]},{"id":"G7","passed":true,"required":true,"reasonCodes":[]},{"id":"G8","passed":true,"required":true,"reasonCodes":[]}],"sourceRole":"published_literature","disposition":"promote_internal","reasonCodes":[],"catastrophic":false,"ownerAuthorized":false,"sourceRoleBasis":"provider_authoritative_index","citationSourceType":"peer_reviewed_research","admitsExactPublishedEvidence":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-09T22:20:33.332Z","updatedAt":"2026-09-09T22:31:57.546Z"},{"id":"d01aa264ec956be6a81ee332490f61a0","peptideId":"3008f1ff-3f15-452c-808d-b8223f27ee12","title":"Multicenter, Observational Study of Lanreotide Autogel for the Treatment of Patients with Neuroendocrine Tumors in Routine Clinical Practice in Germany and Austria.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/34293802/","evidenceTier":"observational","summary":"The long-acting somatostatin analog lanreotide autogel is effective in the treatment of patients with neuroendocrine tumors.","authors":"Anja Rinke, Christoph Maintz, Lothar Müller, Matthias M Weber, Harald Lahner, Marianne Pavel, Wolfgang Saeger, Aude Houchard, Hanna Ungewiss, Stephan Petersenn","publishingOrg":"Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","publicationYear":2021,"doi":"10.1055/a-1342-2755","pubmedId":"34293802","jurisdiction":null,"dateAccessed":"2026-09-09T22:20:33.332Z","editorialNotes":"Identity and metadata verified against the NCBI PubMed record; evidence strength is provisional pending Owner review.","sourceType":"peer_reviewed_research","claimSupported":"Directly informs the Lanreotide evidence profile within the limits of its study design.","supportNature":"Direct or contextual support; no extrapolation beyond the source design.","qualification":"Publication identity verified; full-text risk-of-bias and applicability require governed review.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-automation-profile-corpus-v1","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1055/a-1342-2755","sourceIdentityId":"b46e66ea2ae953c67b14fbd51f7af1ca","sourceStatus":"active","sourceContentHash":"471eb3519ba45cccddc4ece63491256c7d11aff17f7bf207a6f37e3d7c5e1f13","sourceVersion":1,"retrievedAt":"2026-09-09T22:20:33.332Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"pubmed:34293802","evidenceLane":"human_observational","extractionPayload":{"outcomes":"No claim-level outcome imported without full-text adjudication.","limitations":"Source identity and relevance verified; detailed risk-of-bias and applicability remain for profile-level Owner review.","studyDesign":"observational, comparative, monitoring, or contextual human study","sourceStrength":{"grade":"B","score":75,"version":"WPF-ESR-1.0","dimensions":{"identity":100,"directness":85,"replication":70,"studyDesign":75,"regulatoryRelevance":60},"provisional":true},"populationOrModel":"See source abstract and full text; identity verified at PubMed."},"provenancePayload":{"doi":"10.1055/a-1342-2755","locator":"https://pubmed.ncbi.nlm.nih.gov/34293802/","provider":"pubmed","sourceRole":"published_literature","retrievedAt":"2026-09-09T21:45:00Z","rawPayloadHash":"471eb3519ba45cccddc4ece63491256c7d11aff17f7bf207a6f37e3d7c5e1f13","sourceRoleBasis":"provider_authoritative_index","providerRecordId":"34293802","rawPayloadReference":"pubmed:34293802"},"validationGates":{"gates":[{"id":"G1","passed":true,"required":true,"reasonCodes":[]},{"id":"G2","passed":true,"required":true,"reasonCodes":[]},{"id":"G3","passed":true,"required":true,"reasonCodes":[]},{"id":"G4","passed":true,"required":true,"reasonCodes":[]},{"id":"G5","passed":true,"required":true,"reasonCodes":[]},{"id":"G6","passed":true,"required":true,"reasonCodes":[]},{"id":"G7","passed":true,"required":true,"reasonCodes":[]},{"id":"G8","passed":true,"required":true,"reasonCodes":[]}],"sourceRole":"published_literature","disposition":"promote_internal","reasonCodes":[],"catastrophic":false,"ownerAuthorized":false,"sourceRoleBasis":"provider_authoritative_index","citationSourceType":"peer_reviewed_research","admitsExactPublishedEvidence":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-09T22:20:33.332Z","updatedAt":"2026-09-09T22:31:57.546Z"},{"id":"5556e83bcc2d0071e02f12bdcdc2a959","peptideId":"3008f1ff-3f15-452c-808d-b8223f27ee12","title":"Efficacy and safety of lanreotide autogel compared with lanreotide 40 mg prolonged release in Chinese patients with active acromegaly: results from a phase 3, prospective, randomized, and open-label study (LANTERN).","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/32366244/","evidenceTier":"phase_3","summary":"Lanreotide autogel is a somatostatin analog (SSA) approved for the treatment of acromegaly in 73 countries worldwide; however, it is not yet approved in China.","authors":"Zhenmei An, Ting Lei, Lian Duan, Pei Hu, Zhongping Gou, Lihui Zhang, Lucie Durand-Gasselin, Nan Wang, Yan Wang, Feng Gu, LANTERN study investigators","publishingOrg":"BMC endocrine disorders","publicationYear":2020,"doi":"10.1186/s12902-020-0524-7","pubmedId":"32366244","jurisdiction":null,"dateAccessed":"2026-09-09T22:20:33.332Z","editorialNotes":"Identity and metadata verified against the NCBI PubMed record; evidence strength is provisional pending Owner review.","sourceType":"peer_reviewed_research","claimSupported":"Directly informs the Lanreotide evidence profile within the limits of its study design.","supportNature":"Direct or contextual support; no extrapolation beyond the source design.","qualification":"Publication identity verified; full-text risk-of-bias and applicability require governed review.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-automation-profile-corpus-v1","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1186/s12902-020-0524-7","sourceIdentityId":"f7e4c0131329ac08147c56178d3ff9a6","sourceStatus":"active","sourceContentHash":"901585e9b191899459418e557b294f5216ee06785e35e8ba19e383c9132ad56b","sourceVersion":1,"retrievedAt":"2026-09-09T22:20:33.332Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"pubmed:32366244","evidenceLane":"human_interventional","extractionPayload":{"outcomes":"No claim-level outcome imported without full-text adjudication.","limitations":"Source identity and relevance verified; detailed risk-of-bias and applicability remain for profile-level Owner review.","studyDesign":"randomized or prospective clinical study","sourceStrength":{"grade":"A","score":91,"version":"WPF-ESR-1.0","dimensions":{"identity":100,"directness":85,"replication":70,"studyDesign":91,"regulatoryRelevance":60},"provisional":true},"populationOrModel":"See source abstract and full text; identity verified at PubMed."},"provenancePayload":{"doi":"10.1186/s12902-020-0524-7","locator":"https://pubmed.ncbi.nlm.nih.gov/32366244/","provider":"pubmed","sourceRole":"published_literature","retrievedAt":"2026-09-09T21:45:00Z","rawPayloadHash":"901585e9b191899459418e557b294f5216ee06785e35e8ba19e383c9132ad56b","sourceRoleBasis":"provider_authoritative_index","providerRecordId":"32366244","rawPayloadReference":"pubmed:32366244"},"validationGates":{"gates":[{"id":"G1","passed":true,"required":true,"reasonCodes":[]},{"id":"G2","passed":true,"required":true,"reasonCodes":[]},{"id":"G3","passed":true,"required":true,"reasonCodes":[]},{"id":"G4","passed":true,"required":true,"reasonCodes":[]},{"id":"G5","passed":true,"required":true,"reasonCodes":[]},{"id":"G6","passed":true,"required":true,"reasonCodes":[]},{"id":"G7","passed":true,"required":true,"reasonCodes":[]},{"id":"G8","passed":true,"required":true,"reasonCodes":[]}],"sourceRole":"published_literature","disposition":"promote_internal","reasonCodes":[],"catastrophic":false,"ownerAuthorized":false,"sourceRoleBasis":"provider_authoritative_index","citationSourceType":"peer_reviewed_research","admitsExactPublishedEvidence":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-09T22:20:33.332Z","updatedAt":"2026-09-09T22:31:57.546Z"},{"id":"3b48a93b8be3f8727c0de88e6db09975","peptideId":"3008f1ff-3f15-452c-808d-b8223f27ee12","title":"Effect of Lanreotide Depot/Autogel on Urinary 5-Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/30355775/","evidenceTier":"phase_3","summary":"Urinary 5-hydroxyindoleacetic acid (5-HIAA) is an established biomarker in neuroendocrine tumors and carcinoid syndrome; however, its role in nonfunctional neuroendocrine tumors is not defined.","authors":"Marianne E Pavel, Alexandria T Phan, Edward M Wolin, Beloo Mirakhur, Nilani Liyanage, Susan Pitman Lowenthal, George A Fisher, Aaron I Vinik, CLARINET Study Investigators","publishingOrg":"The oncologist","publicationYear":2019,"doi":"10.1634/theoncologist.2018-0217","pubmedId":"30355775","jurisdiction":null,"dateAccessed":"2026-09-09T22:20:33.332Z","editorialNotes":"Identity and metadata verified against the NCBI PubMed record; evidence strength is provisional pending Owner review.","sourceType":"peer_reviewed_research","claimSupported":"Directly informs the Lanreotide evidence profile within the limits of its study design.","supportNature":"Direct or contextual support; no extrapolation beyond the source design.","qualification":"Publication identity verified; full-text risk-of-bias and applicability require governed review.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-automation-profile-corpus-v1","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1634/theoncologist.2018-0217","sourceIdentityId":"5f1d513ba9403a3c81ee7cf44d8a5a42","sourceStatus":"active","sourceContentHash":"fddb549af08d63fc7934bfb3c23ba55d218ce6fd60fe8d663d7a3375ff8124e1","sourceVersion":1,"retrievedAt":"2026-09-09T22:20:33.332Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"pubmed:30355775","evidenceLane":"human_interventional","extractionPayload":{"outcomes":"No claim-level outcome imported without full-text adjudication.","limitations":"Source identity and relevance verified; detailed risk-of-bias and applicability remain for profile-level Owner review.","studyDesign":"randomized or prospective clinical study","sourceStrength":{"grade":"A","score":91,"version":"WPF-ESR-1.0","dimensions":{"identity":100,"directness":85,"replication":70,"studyDesign":91,"regulatoryRelevance":60},"provisional":true},"populationOrModel":"See source abstract and full text; identity verified at PubMed."},"provenancePayload":{"doi":"10.1634/theoncologist.2018-0217","locator":"https://pubmed.ncbi.nlm.nih.gov/30355775/","provider":"pubmed","sourceRole":"published_literature","retrievedAt":"2026-09-09T21:45:00Z","rawPayloadHash":"fddb549af08d63fc7934bfb3c23ba55d218ce6fd60fe8d663d7a3375ff8124e1","sourceRoleBasis":"provider_authoritative_index","providerRecordId":"30355775","rawPayloadReference":"pubmed:30355775"},"validationGates":{"gates":[{"id":"G1","passed":true,"required":true,"reasonCodes":[]},{"id":"G2","passed":true,"required":true,"reasonCodes":[]},{"id":"G3","passed":true,"required":true,"reasonCodes":[]},{"id":"G4","passed":true,"required":true,"reasonCodes":[]},{"id":"G5","passed":true,"required":true,"reasonCodes":[]},{"id":"G6","passed":true,"required":true,"reasonCodes":[]},{"id":"G7","passed":true,"required":true,"reasonCodes":[]},{"id":"G8","passed":true,"required":true,"reasonCodes":[]}],"sourceRole":"published_literature","disposition":"promote_internal","reasonCodes":[],"catastrophic":false,"ownerAuthorized":false,"sourceRoleBasis":"provider_authoritative_index","citationSourceType":"peer_reviewed_research","admitsExactPublishedEvidence":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-09T22:20:33.332Z","updatedAt":"2026-09-09T22:31:57.546Z"},{"id":"dea9bd85370c440260fc28ff2e6c1259","peptideId":"3008f1ff-3f15-452c-808d-b8223f27ee12","title":"Lanreotide Reduces Liver Growth In Patients With Autosomal Dominant Polycystic Liver and Kidney Disease.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/31022403/","evidenceTier":"phase_1_2","summary":"Polycystic liver disease is the most common extrarenal manifestation of autosomal dominant polycystic kidney disease (ADPKD).","authors":"Rene M M van Aerts, Wietske Kievit, Hedwig M A D'Agnolo, Charles J Blijdorp, Niek F Casteleijn, Shosha E I Dekker, Johan W de Fijter, Maatje van Gastel, Tom J Gevers, Liyanne F M van de Laarschot, Marten A Lantinga, Monique Losekoot","publishingOrg":"Gastroenterology","publicationYear":2019,"doi":"10.1053/j.gastro.2019.04.018","pubmedId":"31022403","jurisdiction":null,"dateAccessed":"2026-09-09T22:20:33.332Z","editorialNotes":"Identity and metadata verified against the NCBI PubMed record; evidence strength is provisional pending Owner review.","sourceType":"peer_reviewed_research","claimSupported":"Directly informs the Lanreotide evidence profile within the limits of its study design.","supportNature":"Direct or contextual support; no extrapolation beyond the source design.","qualification":"Publication identity verified; full-text risk-of-bias and applicability require governed review.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-automation-profile-corpus-v1","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1053/j.gastro.2019.04.018","sourceIdentityId":"9d9c6af46b378a74dd9309e6dae4f242","sourceStatus":"active","sourceContentHash":"9bebe0787d0ef529dc3e97290d153a7618315a90fb205b60de71b68dfda70fd8","sourceVersion":1,"retrievedAt":"2026-09-09T22:20:33.332Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"pubmed:31022403","evidenceLane":"human_interventional","extractionPayload":{"outcomes":"No claim-level outcome imported without full-text adjudication.","limitations":"Source identity and relevance verified; detailed risk-of-bias and applicability remain for profile-level Owner review.","studyDesign":"randomized or prospective clinical study","sourceStrength":{"grade":"B","score":80,"version":"WPF-ESR-1.0","dimensions":{"identity":100,"directness":85,"replication":70,"studyDesign":80,"regulatoryRelevance":60},"provisional":true},"populationOrModel":"See source abstract and full text; identity verified at PubMed."},"provenancePayload":{"doi":"10.1053/j.gastro.2019.04.018","locator":"https://pubmed.ncbi.nlm.nih.gov/31022403/","provider":"pubmed","sourceRole":"published_literature","retrievedAt":"2026-09-09T21:45:00Z","rawPayloadHash":"9bebe0787d0ef529dc3e97290d153a7618315a90fb205b60de71b68dfda70fd8","sourceRoleBasis":"provider_authoritative_index","providerRecordId":"31022403","rawPayloadReference":"pubmed:31022403"},"validationGates":{"gates":[{"id":"G1","passed":true,"required":true,"reasonCodes":[]},{"id":"G2","passed":true,"required":true,"reasonCodes":[]},{"id":"G3","passed":true,"required":true,"reasonCodes":[]},{"id":"G4","passed":true,"required":true,"reasonCodes":[]},{"id":"G5","passed":true,"required":true,"reasonCodes":[]},{"id":"G6","passed":true,"required":true,"reasonCodes":[]},{"id":"G7","passed":true,"required":true,"reasonCodes":[]},{"id":"G8","passed":true,"required":true,"reasonCodes":[]}],"sourceRole":"published_literature","disposition":"promote_internal","reasonCodes":[],"catastrophic":false,"ownerAuthorized":false,"sourceRoleBasis":"provider_authoritative_index","citationSourceType":"peer_reviewed_research","admitsExactPublishedEvidence":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-09T22:20:33.332Z","updatedAt":"2026-09-09T22:31:57.546Z"},{"id":"604d6869f08e510c7451b8ce1094eacd","peptideId":"3008f1ff-3f15-452c-808d-b8223f27ee12","title":"Effect of Lanreotide on Kidney Function in Patients With Autosomal Dominant Polycystic Kidney Disease: The DIPAK 1 Randomized Clinical Trial.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/30422235/","evidenceTier":"phase_1_2","summary":"Autosomal dominant polycystic kidney disease (ADPKD) is characterized by progressive cyst formation in both kidneys and loss of renal function, eventually leading to a need for kidney replacement therapy.","authors":"Esther Meijer, Folkert W Visser, Rene M M van Aerts, Charles J Blijdorp, Niek F Casteleijn, Hedwig M A D'Agnolo, Shosha E I Dekker, Joost P H Drenth, Johan W de Fijter, Maatje D A van Gastel, Tom J Gevers, Marten A Lantinga","publishingOrg":"JAMA","publicationYear":2018,"doi":"10.1001/jama.2018.15870","pubmedId":"30422235","jurisdiction":null,"dateAccessed":"2026-09-09T22:20:33.332Z","editorialNotes":"Identity and metadata verified against the NCBI PubMed record; evidence strength is provisional pending Owner review.","sourceType":"peer_reviewed_research","claimSupported":"Directly informs the Lanreotide evidence profile within the limits of its study design.","supportNature":"Direct or contextual support; no extrapolation beyond the source design.","qualification":"Publication identity verified; full-text risk-of-bias and applicability require governed review.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-automation-profile-corpus-v1","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1001/jama.2018.15870","sourceIdentityId":"0fe31d87890a3fed1434986a909e6988","sourceStatus":"active","sourceContentHash":"024b0d361f16843c25632374e41ce24c08bf6262da5f9f1ee831cf9d95b96bc3","sourceVersion":1,"retrievedAt":"2026-09-09T22:20:33.332Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"pubmed:30422235","evidenceLane":"human_interventional","extractionPayload":{"outcomes":"No claim-level outcome imported without full-text adjudication.","limitations":"Source identity and relevance verified; detailed risk-of-bias and applicability remain for profile-level Owner review.","studyDesign":"randomized or prospective clinical study","sourceStrength":{"grade":"B","score":80,"version":"WPF-ESR-1.0","dimensions":{"identity":100,"directness":85,"replication":70,"studyDesign":80,"regulatoryRelevance":60},"provisional":true},"populationOrModel":"See source abstract and full text; identity verified at PubMed."},"provenancePayload":{"doi":"10.1001/jama.2018.15870","locator":"https://pubmed.ncbi.nlm.nih.gov/30422235/","provider":"pubmed","sourceRole":"published_literature","retrievedAt":"2026-09-09T21:45:00Z","rawPayloadHash":"024b0d361f16843c25632374e41ce24c08bf6262da5f9f1ee831cf9d95b96bc3","sourceRoleBasis":"provider_authoritative_index","providerRecordId":"30422235","rawPayloadReference":"pubmed:30422235"},"validationGates":{"gates":[{"id":"G1","passed":true,"required":true,"reasonCodes":[]},{"id":"G2","passed":true,"required":true,"reasonCodes":[]},{"id":"G3","passed":true,"required":true,"reasonCodes":[]},{"id":"G4","passed":true,"required":true,"reasonCodes":[]},{"id":"G5","passed":true,"required":true,"reasonCodes":[]},{"id":"G6","passed":true,"required":true,"reasonCodes":[]},{"id":"G7","passed":true,"required":true,"reasonCodes":[]},{"id":"G8","passed":true,"required":true,"reasonCodes":[]}],"sourceRole":"published_literature","disposition":"promote_internal","reasonCodes":[],"catastrophic":false,"ownerAuthorized":false,"sourceRoleBasis":"provider_authoritative_index","citationSourceType":"peer_reviewed_research","admitsExactPublishedEvidence":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-09T22:20:33.332Z","updatedAt":"2026-09-09T22:31:57.546Z"},{"id":"84af84e4773dd681932d60859e4b0175","peptideId":"3008f1ff-3f15-452c-808d-b8223f27ee12","title":"LANREOTIDE THERAPY IN CARCINOID SYNDROME: PROSPECTIVE ANALYSIS OF PATIENT-REPORTED SYMPTOMS IN PATIENTS RESPONSIVE TO PRIOR OCTREOTIDE THERAPY AND PATIENTS NAÏVE TO SOMATOSTATIN ANALOGUE THERAPY IN THE ELECT PHASE 3 STUDY.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/29547049/","evidenceTier":"phase_3","summary":"This ELECT prospective analysis examined lanreotide depot/autogel for carcinoid syndrome (CS) symptom control in patients with neuroendocrine tumors (NETs) who were responsive to prior octreotide (prior octreotide group) compared with patients who were naïve to prior somatostatin analogue treatment (de novo group).","authors":"George A Fisher, Edward M Wolin, Nilani Liyanage, Susan Pitman Lowenthal, Beloo Mirakhur, Rodney F Pommier, Montaser Shaheen, Aaron I Vinik, ELECT Study Investigators","publishingOrg":"Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","publicationYear":2018,"doi":"10.4158/ep172000.or","pubmedId":"29547049","jurisdiction":null,"dateAccessed":"2026-09-09T22:20:33.332Z","editorialNotes":"Identity and metadata verified against the NCBI PubMed record; evidence strength is provisional pending Owner review.","sourceType":"peer_reviewed_research","claimSupported":"Directly informs the Lanreotide evidence profile within the limits of its study design.","supportNature":"Direct or contextual support; no extrapolation beyond the source design.","qualification":"Publication identity verified; full-text risk-of-bias and applicability require governed review.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-automation-profile-corpus-v1","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.4158/ep172000.or","sourceIdentityId":"0cd1d65e5b518aaa6d8f03a0d3fdeb65","sourceStatus":"active","sourceContentHash":"a1390846246390092b2e4ee23d652cbe217d4ebec6119574fd5a33b6c9441940","sourceVersion":1,"retrievedAt":"2026-09-09T22:20:33.332Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"pubmed:29547049","evidenceLane":"human_interventional","extractionPayload":{"outcomes":"No claim-level outcome imported without full-text adjudication.","limitations":"Source identity and relevance verified; detailed risk-of-bias and applicability remain for profile-level Owner review.","studyDesign":"randomized or prospective clinical study","sourceStrength":{"grade":"A","score":91,"version":"WPF-ESR-1.0","dimensions":{"identity":100,"directness":85,"replication":70,"studyDesign":91,"regulatoryRelevance":60},"provisional":true},"populationOrModel":"See source abstract and full text; identity verified at PubMed."},"provenancePayload":{"doi":"10.4158/EP172000.OR","locator":"https://pubmed.ncbi.nlm.nih.gov/29547049/","provider":"pubmed","sourceRole":"published_literature","retrievedAt":"2026-09-09T21:45:00Z","rawPayloadHash":"a1390846246390092b2e4ee23d652cbe217d4ebec6119574fd5a33b6c9441940","sourceRoleBasis":"provider_authoritative_index","providerRecordId":"29547049","rawPayloadReference":"pubmed:29547049"},"validationGates":{"gates":[{"id":"G1","passed":true,"required":true,"reasonCodes":[]},{"id":"G2","passed":true,"required":true,"reasonCodes":[]},{"id":"G3","passed":true,"required":true,"reasonCodes":[]},{"id":"G4","passed":true,"required":true,"reasonCodes":[]},{"id":"G5","passed":true,"required":true,"reasonCodes":[]},{"id":"G6","passed":true,"required":true,"reasonCodes":[]},{"id":"G7","passed":true,"required":true,"reasonCodes":[]},{"id":"G8","passed":true,"required":true,"reasonCodes":[]}],"sourceRole":"published_literature","disposition":"promote_internal","reasonCodes":[],"catastrophic":false,"ownerAuthorized":false,"sourceRoleBasis":"provider_authoritative_index","citationSourceType":"peer_reviewed_research","admitsExactPublishedEvidence":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-09T22:20:33.332Z","updatedAt":"2026-09-09T22:31:57.546Z"},{"id":"0e31c971db65cc9b7e1c47877094487a","peptideId":"3008f1ff-3f15-452c-808d-b8223f27ee12","title":"The Antiproliferative Role of Lanreotide in Controlling Growth of Neuroendocrine Tumors: A Systematic Review.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/28220021/","evidenceTier":"observational","summary":"Neuroendocrine tumors (NETs) are a heterogeneous group of tumors, with >50% of cases involving the gastrointestinal system or pancreas.","authors":"Michael Michael, Rocio Garcia-Carbonero, Matthias M Weber, Catherine Lombard-Bohas, Christos Toumpanakis, Rodney J Hicks","publishingOrg":"The oncologist","publicationYear":2017,"doi":"10.1634/theoncologist.2016-0305","pubmedId":"28220021","jurisdiction":null,"dateAccessed":"2026-09-09T22:20:33.332Z","editorialNotes":"Identity and metadata verified against the NCBI PubMed record; evidence strength is provisional pending Owner review.","sourceType":"systematic_review_or_meta_analysis","claimSupported":"Directly informs the Lanreotide evidence profile within the limits of its study design.","supportNature":"Direct or contextual support; no extrapolation beyond the source design.","qualification":"Publication identity verified; full-text risk-of-bias and applicability require governed review.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-automation-profile-corpus-v1","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1634/theoncologist.2016-0305","sourceIdentityId":"51e1e193c12e19aa66e6959b14c12b1d","sourceStatus":"active","sourceContentHash":"cdeaa487b272deeff6e38704f44c172dfa1d047a048534274f2d32b55920775b","sourceVersion":1,"retrievedAt":"2026-09-09T22:20:33.332Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"pubmed:28220021","evidenceLane":"systematic_review","extractionPayload":{"outcomes":"No claim-level outcome imported without full-text adjudication.","limitations":"Source identity and relevance verified; detailed risk-of-bias and applicability remain for profile-level Owner review.","studyDesign":"systematic review","sourceStrength":{"grade":"A","score":86,"version":"WPF-ESR-1.0","dimensions":{"identity":100,"directness":85,"replication":70,"studyDesign":86,"regulatoryRelevance":60},"provisional":true},"populationOrModel":"See source abstract and full text; identity verified at PubMed."},"provenancePayload":{"doi":"10.1634/theoncologist.2016-0305","locator":"https://pubmed.ncbi.nlm.nih.gov/28220021/","provider":"pubmed","sourceRole":"published_literature","retrievedAt":"2026-09-09T21:45:00Z","rawPayloadHash":"cdeaa487b272deeff6e38704f44c172dfa1d047a048534274f2d32b55920775b","sourceRoleBasis":"provider_authoritative_index","providerRecordId":"28220021","rawPayloadReference":"pubmed:28220021"},"validationGates":{"gates":[{"id":"G1","passed":true,"required":true,"reasonCodes":[]},{"id":"G2","passed":true,"required":true,"reasonCodes":[]},{"id":"G3","passed":true,"required":true,"reasonCodes":[]},{"id":"G4","passed":true,"required":true,"reasonCodes":[]},{"id":"G5","passed":true,"required":true,"reasonCodes":[]},{"id":"G6","passed":true,"required":true,"reasonCodes":[]},{"id":"G7","passed":true,"required":true,"reasonCodes":[]},{"id":"G8","passed":true,"required":true,"reasonCodes":[]}],"sourceRole":"published_literature","disposition":"promote_internal","reasonCodes":[],"catastrophic":false,"ownerAuthorized":false,"sourceRoleBasis":"provider_authoritative_index","citationSourceType":"systematic_review_or_meta_analysis","admitsExactPublishedEvidence":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-09T22:20:33.332Z","updatedAt":"2026-09-09T22:31:57.546Z"},{"id":"611eb4b120833e0cbe9355c2c21ca327","peptideId":"3008f1ff-3f15-452c-808d-b8223f27ee12","title":"Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/26743120/","evidenceTier":"phase_1_2","summary":"In the CLARINET study, lanreotide Autogel (depot in USA) significantly prolonged progression-free survival (PFS) in patients with metastatic pancreatic/intestinal neuroendocrine tumours (NETs).","authors":"Martyn E Caplin, Marianne Pavel, Jarosław B Ćwikła, Alexandria T Phan, Markus Raderer, Eva Sedláčková, Guillaume Cadiot, Edward M Wolin, Jaume Capdevila, Lucy Wall, Guido Rindi, Alison Langley","publishingOrg":"Endocrine-related cancer","publicationYear":2016,"doi":"10.1530/erc-15-0490","pubmedId":"26743120","jurisdiction":null,"dateAccessed":"2026-09-09T22:20:33.332Z","editorialNotes":"Identity and metadata verified against the NCBI PubMed record; evidence strength is provisional pending Owner review.","sourceType":"peer_reviewed_research","claimSupported":"Directly informs the Lanreotide evidence profile within the limits of its study design.","supportNature":"Direct or contextual support; no extrapolation beyond the source design.","qualification":"Publication identity verified; full-text risk-of-bias and applicability require governed review.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-automation-profile-corpus-v1","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1530/erc-15-0490","sourceIdentityId":"dd12888bab47244239b1eff28608773c","sourceStatus":"active","sourceContentHash":"08610c92a57407da106c299e759986ab51fb54c7307eccabdc24f0bc6a9cd2ee","sourceVersion":1,"retrievedAt":"2026-09-09T22:20:33.332Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"pubmed:26743120","evidenceLane":"human_interventional","extractionPayload":{"outcomes":"No claim-level outcome imported without full-text adjudication.","limitations":"Source identity and relevance verified; detailed risk-of-bias and applicability remain for profile-level Owner review.","studyDesign":"randomized or prospective clinical study","sourceStrength":{"grade":"B","score":80,"version":"WPF-ESR-1.0","dimensions":{"identity":100,"directness":85,"replication":70,"studyDesign":80,"regulatoryRelevance":60},"provisional":true},"populationOrModel":"See source abstract and full text; identity verified at PubMed."},"provenancePayload":{"doi":"10.1530/ERC-15-0490","locator":"https://pubmed.ncbi.nlm.nih.gov/26743120/","provider":"pubmed","sourceRole":"published_literature","retrievedAt":"2026-09-09T21:45:00Z","rawPayloadHash":"08610c92a57407da106c299e759986ab51fb54c7307eccabdc24f0bc6a9cd2ee","sourceRoleBasis":"provider_authoritative_index","providerRecordId":"26743120","rawPayloadReference":"pubmed:26743120"},"validationGates":{"gates":[{"id":"G1","passed":true,"required":true,"reasonCodes":[]},{"id":"G2","passed":true,"required":true,"reasonCodes":[]},{"id":"G3","passed":true,"required":true,"reasonCodes":[]},{"id":"G4","passed":true,"required":true,"reasonCodes":[]},{"id":"G5","passed":true,"required":true,"reasonCodes":[]},{"id":"G6","passed":true,"required":true,"reasonCodes":[]},{"id":"G7","passed":true,"required":true,"reasonCodes":[]},{"id":"G8","passed":true,"required":true,"reasonCodes":[]}],"sourceRole":"published_literature","disposition":"promote_internal","reasonCodes":[],"catastrophic":false,"ownerAuthorized":false,"sourceRoleBasis":"provider_authoritative_index","citationSourceType":"peer_reviewed_research","admitsExactPublishedEvidence":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-09T22:20:33.332Z","updatedAt":"2026-09-09T22:31:57.546Z"},{"id":"a4b0cf9a132eed02d27970f61dca9ccd","peptideId":"3008f1ff-3f15-452c-808d-b8223f27ee12","title":"EVALUATION OF LANREOTIDE DEPOT/AUTOGEL EFFICACY AND SAFETY AS A CARCINOID SYNDROME TREATMENT (ELECT): A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/27214300/","evidenceTier":"phase_3","summary":"To evaluate the efficacy and safety of lanreotide depot/autogel 120 mg for the control of carcinoid syndrome (CS) symptoms in patients with neuroendocrine tumors (NETs).","authors":"Aaron I Vinik, Edward M Wolin, Nilani Liyanage, Edda Gomez-Panzani, George A Fisher, ELECT Study Group *","publishingOrg":"Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists","publicationYear":2016,"doi":"10.4158/ep151172.or","pubmedId":"27214300","jurisdiction":null,"dateAccessed":"2026-09-09T22:20:33.332Z","editorialNotes":"Identity and metadata verified against the NCBI PubMed record; evidence strength is provisional pending Owner review.","sourceType":"peer_reviewed_research","claimSupported":"Directly informs the Lanreotide evidence profile within the limits of its study design.","supportNature":"Direct or contextual support; no extrapolation beyond the source design.","qualification":"Publication identity verified; full-text risk-of-bias and applicability require governed review.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-automation-profile-corpus-v1","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.4158/ep151172.or","sourceIdentityId":"e691d4c1492277b6bc3d239db0902dbb","sourceStatus":"active","sourceContentHash":"f7edb01cbf8276fae1420724a318fbda75a37e7a98156aa86c88c13108686d20","sourceVersion":1,"retrievedAt":"2026-09-09T22:20:33.332Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"pubmed:27214300","evidenceLane":"human_interventional","extractionPayload":{"outcomes":"No claim-level outcome imported without full-text adjudication.","limitations":"Source identity and relevance verified; detailed risk-of-bias and applicability remain for profile-level Owner review.","studyDesign":"randomized or prospective clinical study","sourceStrength":{"grade":"A","score":91,"version":"WPF-ESR-1.0","dimensions":{"identity":100,"directness":85,"replication":70,"studyDesign":91,"regulatoryRelevance":60},"provisional":true},"populationOrModel":"See source abstract and full text; identity verified at PubMed."},"provenancePayload":{"doi":"10.4158/EP151172.OR","locator":"https://pubmed.ncbi.nlm.nih.gov/27214300/","provider":"pubmed","sourceRole":"published_literature","retrievedAt":"2026-09-09T21:45:00Z","rawPayloadHash":"f7edb01cbf8276fae1420724a318fbda75a37e7a98156aa86c88c13108686d20","sourceRoleBasis":"provider_authoritative_index","providerRecordId":"27214300","rawPayloadReference":"pubmed:27214300"},"validationGates":{"gates":[{"id":"G1","passed":true,"required":true,"reasonCodes":[]},{"id":"G2","passed":true,"required":true,"reasonCodes":[]},{"id":"G3","passed":true,"required":true,"reasonCodes":[]},{"id":"G4","passed":true,"required":true,"reasonCodes":[]},{"id":"G5","passed":true,"required":true,"reasonCodes":[]},{"id":"G6","passed":true,"required":true,"reasonCodes":[]},{"id":"G7","passed":true,"required":true,"reasonCodes":[]},{"id":"G8","passed":true,"required":true,"reasonCodes":[]}],"sourceRole":"published_literature","disposition":"promote_internal","reasonCodes":[],"catastrophic":false,"ownerAuthorized":false,"sourceRoleBasis":"provider_authoritative_index","citationSourceType":"peer_reviewed_research","admitsExactPublishedEvidence":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-09T22:20:33.332Z","updatedAt":"2026-09-09T22:31:57.546Z"},{"id":"00ea1c0ec63a3d40afa90b6f2997024c","peptideId":"3008f1ff-3f15-452c-808d-b8223f27ee12","title":"Effects of lanreotide Autogel primary therapy on symptoms and quality-of-life in acromegaly: data from the PRIMARYS study.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/26603536/","evidenceTier":"phase_3","summary":"To evaluate the effects of lanreotide Autogel on patient-reported outcomes and association with biochemical control, using PRIMARYS data.","authors":"Philippe J Caron, John S Bevan, Stephan Petersenn, Aude Houchard, Caroline Sert, Susan M Webb, PRIMARYS Investigators Group","publishingOrg":"Pituitary","publicationYear":2016,"doi":"10.1007/s11102-015-0693-y","pubmedId":"26603536","jurisdiction":null,"dateAccessed":"2026-09-09T22:20:33.332Z","editorialNotes":"Identity and metadata verified against the NCBI PubMed record; evidence strength is provisional pending Owner review.","sourceType":"peer_reviewed_research","claimSupported":"Directly informs the Lanreotide evidence profile within the limits of its study design.","supportNature":"Direct or contextual support; no extrapolation beyond the source design.","qualification":"Publication identity verified; full-text risk-of-bias and applicability require governed review.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-automation-profile-corpus-v1","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1007/s11102-015-0693-y","sourceIdentityId":"256fdb678dc1d56f539b7896ba0ac656","sourceStatus":"active","sourceContentHash":"98edf24e653573e42e9dfdb2e6a666d59c716127394bc96da151a60f9c706ea6","sourceVersion":1,"retrievedAt":"2026-09-09T22:20:33.332Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"pubmed:26603536","evidenceLane":"human_interventional","extractionPayload":{"outcomes":"No claim-level outcome imported without full-text adjudication.","limitations":"Source identity and relevance verified; detailed risk-of-bias and applicability remain for profile-level Owner review.","studyDesign":"randomized or prospective clinical study","sourceStrength":{"grade":"A","score":91,"version":"WPF-ESR-1.0","dimensions":{"identity":100,"directness":85,"replication":70,"studyDesign":91,"regulatoryRelevance":60},"provisional":true},"populationOrModel":"See source abstract and full text; identity verified at PubMed."},"provenancePayload":{"doi":"10.1007/s11102-015-0693-y","locator":"https://pubmed.ncbi.nlm.nih.gov/26603536/","provider":"pubmed","sourceRole":"published_literature","retrievedAt":"2026-09-09T21:45:00Z","rawPayloadHash":"98edf24e653573e42e9dfdb2e6a666d59c716127394bc96da151a60f9c706ea6","sourceRoleBasis":"provider_authoritative_index","providerRecordId":"26603536","rawPayloadReference":"pubmed:26603536"},"validationGates":{"gates":[{"id":"G1","passed":true,"required":true,"reasonCodes":[]},{"id":"G2","passed":true,"required":true,"reasonCodes":[]},{"id":"G3","passed":true,"required":true,"reasonCodes":[]},{"id":"G4","passed":true,"required":true,"reasonCodes":[]},{"id":"G5","passed":true,"required":true,"reasonCodes":[]},{"id":"G6","passed":true,"required":true,"reasonCodes":[]},{"id":"G7","passed":true,"required":true,"reasonCodes":[]},{"id":"G8","passed":true,"required":true,"reasonCodes":[]}],"sourceRole":"published_literature","disposition":"promote_internal","reasonCodes":[],"catastrophic":false,"ownerAuthorized":false,"sourceRoleBasis":"provider_authoritative_index","citationSourceType":"peer_reviewed_research","admitsExactPublishedEvidence":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-09T22:20:33.332Z","updatedAt":"2026-09-09T22:31:57.546Z"},{"id":"216b89655f32d1a32103898842c1f43d","peptideId":"3008f1ff-3f15-452c-808d-b8223f27ee12","title":"Patient-reported outcomes with lanreotide Autogel/Depot for carcinoid syndrome: An international observational study.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/26917486/","evidenceTier":"observational","summary":"Lanreotide Autogel/Depot effectively controls symptoms in patients with carcinoid syndrome associated with neuroendocrine tumours.","authors":"Philippe Ruszniewski, Juan W Valle, Catherine Lombard-Bohas, Daniel J Cuthbertson, Petros Perros, Luboš Holubec, Gianfranco Delle Fave, Denis Smith, Patricia Niccoli, Pascal Maisonobe, Philippe Atlan, Martyn E Caplin","publishingOrg":"Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver","publicationYear":2016,"doi":"10.1016/j.dld.2015.12.013","pubmedId":"26917486","jurisdiction":null,"dateAccessed":"2026-09-09T22:20:33.332Z","editorialNotes":"Identity and metadata verified against the NCBI PubMed record; evidence strength is provisional pending Owner review.","sourceType":"peer_reviewed_research","claimSupported":"Directly informs the Lanreotide evidence profile within the limits of its study design.","supportNature":"Direct or contextual support; no extrapolation beyond the source design.","qualification":"Publication identity verified; full-text risk-of-bias and applicability require governed review.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-automation-profile-corpus-v1","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1016/j.dld.2015.12.013","sourceIdentityId":"ac879a234b52c7f1dc69f8942b2418bc","sourceStatus":"active","sourceContentHash":"34d0bf645e6ec033d1f4ed7b90c251abce539809f4b2c882cbc86c161c638941","sourceVersion":1,"retrievedAt":"2026-09-09T22:20:33.332Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"pubmed:26917486","evidenceLane":"human_observational","extractionPayload":{"outcomes":"No claim-level outcome imported without full-text adjudication.","limitations":"Source identity and relevance verified; detailed risk-of-bias and applicability remain for profile-level Owner review.","studyDesign":"observational, comparative, monitoring, or contextual human study","sourceStrength":{"grade":"B","score":75,"version":"WPF-ESR-1.0","dimensions":{"identity":100,"directness":85,"replication":70,"studyDesign":75,"regulatoryRelevance":60},"provisional":true},"populationOrModel":"See source abstract and full text; identity verified at PubMed."},"provenancePayload":{"doi":"10.1016/j.dld.2015.12.013","locator":"https://pubmed.ncbi.nlm.nih.gov/26917486/","provider":"pubmed","sourceRole":"published_literature","retrievedAt":"2026-09-09T21:45:00Z","rawPayloadHash":"34d0bf645e6ec033d1f4ed7b90c251abce539809f4b2c882cbc86c161c638941","sourceRoleBasis":"provider_authoritative_index","providerRecordId":"26917486","rawPayloadReference":"pubmed:26917486"},"validationGates":{"gates":[{"id":"G1","passed":true,"required":true,"reasonCodes":[]},{"id":"G2","passed":true,"required":true,"reasonCodes":[]},{"id":"G3","passed":true,"required":true,"reasonCodes":[]},{"id":"G4","passed":true,"required":true,"reasonCodes":[]},{"id":"G5","passed":true,"required":true,"reasonCodes":[]},{"id":"G6","passed":true,"required":true,"reasonCodes":[]},{"id":"G7","passed":true,"required":true,"reasonCodes":[]},{"id":"G8","passed":true,"required":true,"reasonCodes":[]}],"sourceRole":"published_literature","disposition":"promote_internal","reasonCodes":[],"catastrophic":false,"ownerAuthorized":false,"sourceRoleBasis":"provider_authoritative_index","citationSourceType":"peer_reviewed_research","admitsExactPublishedEvidence":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-09T22:20:33.332Z","updatedAt":"2026-09-09T22:31:57.546Z"},{"id":"2f748d42b788b3ef04182c86c85d9618","peptideId":"3008f1ff-3f15-452c-808d-b8223f27ee12","title":"Lanreotide in metastatic enteropancreatic neuroendocrine tumors.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/25014687/","evidenceTier":"phase_3","summary":"Somatostatin analogues are commonly used to treat symptoms associated with hormone hypersecretion in neuroendocrine tumors; however, data on their antitumor effects are limited.","authors":"Martyn E Caplin, Marianne Pavel, Jarosław B Ćwikła, Alexandria T Phan, Markus Raderer, Eva Sedláčková, Guillaume Cadiot, Edward M Wolin, Jaume Capdevila, Lucy Wall, Guido Rindi, Alison Langley","publishingOrg":"The New England journal of medicine","publicationYear":2014,"doi":"10.1056/nejmoa1316158","pubmedId":"25014687","jurisdiction":null,"dateAccessed":"2026-09-09T22:20:33.332Z","editorialNotes":"Identity and metadata verified against the NCBI PubMed record; evidence strength is provisional pending Owner review.","sourceType":"peer_reviewed_research","claimSupported":"Directly informs the Lanreotide evidence profile within the limits of its study design.","supportNature":"Direct or contextual support; no extrapolation beyond the source design.","qualification":"Publication identity verified; full-text risk-of-bias and applicability require governed review.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-automation-profile-corpus-v1","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1056/nejmoa1316158","sourceIdentityId":"2fccacddd0f2f742b00113bbd2a1cf86","sourceStatus":"active","sourceContentHash":"44c964ad4233ddc1681eb15cbca919a25ee0ee1928c411b0675157adb3761a46","sourceVersion":1,"retrievedAt":"2026-09-11T09:01:52.673Z","retrievalProvider":"pubmed","retrievalPayloadRef":"pubmed:25014687","evidenceLane":null,"extractionPayload":null,"provenancePayload":{"locator":"https://pubmed.ncbi.nlm.nih.gov/25014687/","provider":"pubmed","sourceRole":"published_literature","retrievedAt":"2026-09-11T09:01:52.673Z","rawPayloadHash":"44c964ad4233ddc1681eb15cbca919a25ee0ee1928c411b0675157adb3761a46","sourceRoleBasis":"provider_authoritative_index","providerRecordId":"25014687","rawPayloadReference":"pubmed:25014687"},"validationGates":{"gates":[{"id":"G1","passed":true,"required":true,"reasonCodes":[]},{"id":"G2","passed":true,"required":true,"reasonCodes":[]},{"id":"G3","passed":true,"required":true,"reasonCodes":[]},{"id":"G4","passed":false,"required":true,"reasonCodes":["extraction_not_grounded_or_verified"]},{"id":"G5","passed":false,"required":true,"reasonCodes":["evidence_lane_unresolved"]},{"id":"G6","passed":true,"required":true,"reasonCodes":[]},{"id":"G7","passed":true,"required":true,"reasonCodes":[]},{"id":"G8","passed":true,"required":true,"reasonCodes":[]}],"sourceRole":"published_literature","disposition":"quarantine","reasonCodes":["extraction_not_grounded_or_verified","evidence_lane_unresolved"],"catastrophic":false,"sourceRoleBasis":"provider_authoritative_index","citationSourceType":"peer_reviewed_research","roleDemotedFromPromotion":[],"admitsExactPublishedEvidence":true},"engineState":"quarantined","engineRunId":"330ff5c6-5bb8-4338-9538-4538ee2afcfa","createdAt":"2026-09-09T22:20:33.332Z","updatedAt":"2026-09-11T09:02:31.846Z"},{"id":"e4b3dfd3889eff9ff4ed5ccc8f54d747","peptideId":"3008f1ff-3f15-452c-808d-b8223f27ee12","title":"Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/25260838/","evidenceTier":"phase_3","summary":"Many patients with acromegaly do not achieve biochemical control despite receiving high doses of the first-generation somatostatin analogues octreotide or lanreotide.","authors":"Mônica R Gadelha, Marcello D Bronstein, Thierry Brue, Mihail Coculescu, Maria Fleseriu, Mirtha Guitelman, Vyacheslav Pronin, Gérald Raverot, Ilan Shimon, Kayo Kodama Lievre, Juergen Fleck, Mounir Aout","publishingOrg":"The lancet. Diabetes & endocrinology","publicationYear":2014,"doi":"10.1016/s2213-8587(14)70169-x","pubmedId":"25260838","jurisdiction":null,"dateAccessed":"2026-09-09T22:20:33.332Z","editorialNotes":"Identity and metadata verified against the NCBI PubMed record; evidence strength is provisional pending Owner review.","sourceType":"peer_reviewed_research","claimSupported":"Directly informs the Lanreotide evidence profile within the limits of its study design.","supportNature":"Direct or contextual support; no extrapolation beyond the source design.","qualification":"Publication identity verified; full-text risk-of-bias and applicability require governed review.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-automation-profile-corpus-v1","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1016/s2213-8587(14)70169-x","sourceIdentityId":"2f74751d805f07ba94cf462e5b9dfeb9","sourceStatus":"active","sourceContentHash":"9d26b79f10bcd376ad246b938f70d5e31781f6c28132376f7cb283e172784a1a","sourceVersion":1,"retrievedAt":"2026-09-09T22:20:33.332Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"pubmed:25260838","evidenceLane":"human_interventional","extractionPayload":{"outcomes":"No claim-level outcome imported without full-text adjudication.","limitations":"Source identity and relevance verified; detailed risk-of-bias and applicability remain for profile-level Owner review.","studyDesign":"randomized or prospective clinical study","sourceStrength":{"grade":"A","score":91,"version":"WPF-ESR-1.0","dimensions":{"identity":100,"directness":85,"replication":70,"studyDesign":91,"regulatoryRelevance":60},"provisional":true},"populationOrModel":"See source abstract and full text; identity verified at PubMed."},"provenancePayload":{"doi":"10.1016/S2213-8587(14)70169-X","locator":"https://pubmed.ncbi.nlm.nih.gov/25260838/","provider":"pubmed","sourceRole":"published_literature","retrievedAt":"2026-09-09T21:45:00Z","rawPayloadHash":"9d26b79f10bcd376ad246b938f70d5e31781f6c28132376f7cb283e172784a1a","sourceRoleBasis":"provider_authoritative_index","providerRecordId":"25260838","rawPayloadReference":"pubmed:25260838"},"validationGates":{"gates":[{"id":"G1","passed":true,"required":true,"reasonCodes":[]},{"id":"G2","passed":true,"required":true,"reasonCodes":[]},{"id":"G3","passed":true,"required":true,"reasonCodes":[]},{"id":"G4","passed":true,"required":true,"reasonCodes":[]},{"id":"G5","passed":true,"required":true,"reasonCodes":[]},{"id":"G6","passed":true,"required":true,"reasonCodes":[]},{"id":"G7","passed":true,"required":true,"reasonCodes":[]},{"id":"G8","passed":true,"required":true,"reasonCodes":[]}],"sourceRole":"published_literature","disposition":"promote_internal","reasonCodes":[],"catastrophic":false,"ownerAuthorized":false,"sourceRoleBasis":"provider_authoritative_index","citationSourceType":"peer_reviewed_research","admitsExactPublishedEvidence":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-09T22:20:33.332Z","updatedAt":"2026-09-09T22:31:57.546Z"},{"id":"d7131c4875f02a4744ec33d00d0dee2a","peptideId":"3008f1ff-3f15-452c-808d-b8223f27ee12","title":"Tumor shrinkage with lanreotide Autogel 120 mg as primary therapy in acromegaly: results of a prospective multicenter clinical trial.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/24423301/","evidenceTier":"phase_3","summary":"Methodological shortcomings often compromise investigations into the effects of primary somatostatin-analog treatment on tumor size in acromegaly.","authors":"Philippe J Caron, John S Bevan, Stephan Petersenn, Daniel Flanagan, Antoine Tabarin, Gaëtan Prévost, Pascal Maisonobe, Antoine Clermont, PRIMARYS Investigators","publishingOrg":"The Journal of clinical endocrinology and metabolism","publicationYear":2014,"doi":"10.1210/jc.2013-3318","pubmedId":"24423301","jurisdiction":null,"dateAccessed":"2026-09-09T22:20:33.332Z","editorialNotes":"Identity and metadata verified against the NCBI PubMed record; evidence strength is provisional pending Owner review.","sourceType":"peer_reviewed_research","claimSupported":"Directly informs the Lanreotide evidence profile within the limits of its study design.","supportNature":"Direct or contextual support; no extrapolation beyond the source design.","qualification":"Publication identity verified; full-text risk-of-bias and applicability require governed review.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-automation-profile-corpus-v1","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1210/jc.2013-3318","sourceIdentityId":"9c7893aed0637e7a20d3747c69598c26","sourceStatus":"active","sourceContentHash":"92839381bf39085ed6c873629701ae0e71289f9736425c1d717da80366475b82","sourceVersion":1,"retrievedAt":"2026-09-09T22:20:33.332Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"pubmed:24423301","evidenceLane":"human_interventional","extractionPayload":{"outcomes":"No claim-level outcome imported without full-text adjudication.","limitations":"Source identity and relevance verified; detailed risk-of-bias and applicability remain for profile-level Owner review.","studyDesign":"randomized or prospective clinical study","sourceStrength":{"grade":"A","score":91,"version":"WPF-ESR-1.0","dimensions":{"identity":100,"directness":85,"replication":70,"studyDesign":91,"regulatoryRelevance":60},"provisional":true},"populationOrModel":"See source abstract and full text; identity verified at PubMed."},"provenancePayload":{"doi":"10.1210/jc.2013-3318","locator":"https://pubmed.ncbi.nlm.nih.gov/24423301/","provider":"pubmed","sourceRole":"published_literature","retrievedAt":"2026-09-09T21:45:00Z","rawPayloadHash":"92839381bf39085ed6c873629701ae0e71289f9736425c1d717da80366475b82","sourceRoleBasis":"provider_authoritative_index","providerRecordId":"24423301","rawPayloadReference":"pubmed:24423301"},"validationGates":{"gates":[{"id":"G1","passed":true,"required":true,"reasonCodes":[]},{"id":"G2","passed":true,"required":true,"reasonCodes":[]},{"id":"G3","passed":true,"required":true,"reasonCodes":[]},{"id":"G4","passed":true,"required":true,"reasonCodes":[]},{"id":"G5","passed":true,"required":true,"reasonCodes":[]},{"id":"G6","passed":true,"required":true,"reasonCodes":[]},{"id":"G7","passed":true,"required":true,"reasonCodes":[]},{"id":"G8","passed":true,"required":true,"reasonCodes":[]}],"sourceRole":"published_literature","disposition":"promote_internal","reasonCodes":[],"catastrophic":false,"ownerAuthorized":false,"sourceRoleBasis":"provider_authoritative_index","citationSourceType":"peer_reviewed_research","admitsExactPublishedEvidence":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-09T22:20:33.332Z","updatedAt":"2026-09-09T22:31:57.546Z"},{"id":"7fcc7b8155a8aa069c0c34dda4862d0a","peptideId":"3008f1ff-3f15-452c-808d-b8223f27ee12","title":"Efficacy, safety, and pharmacokinetics of sustained-release lanreotide (lanreotide Autogel) in Japanese patients with acromegaly or pituitary gigantism.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/23337477/","evidenceTier":"phase_3","summary":"The somatostatin analog lanreotide Autogel has proven to be efficacious for treating acromegaly in international studies and in clinical practices around the world.","authors":"Akira Shimatsu, Akira Teramoto, Naomi Hizuka, Kazuo Kitai, Joaquim Ramis, Kazuo Chihara","publishingOrg":"Endocrine journal","publicationYear":2013,"doi":"10.1507/endocrj.ej12-0417","pubmedId":"23337477","jurisdiction":null,"dateAccessed":"2026-09-09T22:20:33.332Z","editorialNotes":"Identity and metadata verified against the NCBI PubMed record; evidence strength is provisional pending Owner review.","sourceType":"peer_reviewed_research","claimSupported":"Directly informs the Lanreotide evidence profile within the limits of its study design.","supportNature":"Direct or contextual support; no extrapolation beyond the source design.","qualification":"Publication identity verified; full-text risk-of-bias and applicability require governed review.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-automation-profile-corpus-v1","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1507/endocrj.ej12-0417","sourceIdentityId":"ccaacae6826b35ae784159fea4050e49","sourceStatus":"active","sourceContentHash":"c86786101df6501356e9ce20f528a8897cbe90b49331d291e1e3ce1538a32b1f","sourceVersion":1,"retrievedAt":"2026-09-09T22:20:33.332Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"pubmed:23337477","evidenceLane":"human_interventional","extractionPayload":{"outcomes":"No claim-level outcome imported without full-text adjudication.","limitations":"Source identity and relevance verified; detailed risk-of-bias and applicability remain for profile-level Owner review.","studyDesign":"randomized or prospective clinical study","sourceStrength":{"grade":"A","score":91,"version":"WPF-ESR-1.0","dimensions":{"identity":100,"directness":85,"replication":70,"studyDesign":91,"regulatoryRelevance":60},"provisional":true},"populationOrModel":"See source abstract and full text; identity verified at PubMed."},"provenancePayload":{"doi":"10.1507/endocrj.ej12-0417","locator":"https://pubmed.ncbi.nlm.nih.gov/23337477/","provider":"pubmed","sourceRole":"published_literature","retrievedAt":"2026-09-09T21:45:00Z","rawPayloadHash":"c86786101df6501356e9ce20f528a8897cbe90b49331d291e1e3ce1538a32b1f","sourceRoleBasis":"provider_authoritative_index","providerRecordId":"23337477","rawPayloadReference":"pubmed:23337477"},"validationGates":{"gates":[{"id":"G1","passed":true,"required":true,"reasonCodes":[]},{"id":"G2","passed":true,"required":true,"reasonCodes":[]},{"id":"G3","passed":true,"required":true,"reasonCodes":[]},{"id":"G4","passed":true,"required":true,"reasonCodes":[]},{"id":"G5","passed":true,"required":true,"reasonCodes":[]},{"id":"G6","passed":true,"required":true,"reasonCodes":[]},{"id":"G7","passed":true,"required":true,"reasonCodes":[]},{"id":"G8","passed":true,"required":true,"reasonCodes":[]}],"sourceRole":"published_literature","disposition":"promote_internal","reasonCodes":[],"catastrophic":false,"ownerAuthorized":false,"sourceRoleBasis":"provider_authoritative_index","citationSourceType":"peer_reviewed_research","admitsExactPublishedEvidence":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-09T22:20:33.332Z","updatedAt":"2026-09-09T22:31:57.546Z"},{"id":"b1b1e76f31eaa3655b012be074aad461","peptideId":"3008f1ff-3f15-452c-808d-b8223f27ee12","title":"Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic review.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/19189218/","evidenceTier":"observational","summary":"Long-acting somatostatin analogs (SSA) are widely used for the treatment of acromegaly achieving biochemical control of the disease in 50-75% of the patients.","authors":"Gherardo Mazziotti, Andrea Giustina","publishingOrg":"Pituitary","publicationYear":2010,"doi":"10.1007/s11102-009-0169-z","pubmedId":"19189218","jurisdiction":null,"dateAccessed":"2026-09-09T22:20:33.332Z","editorialNotes":"Identity and metadata verified against the NCBI PubMed record; evidence strength is provisional pending Owner review.","sourceType":"systematic_review_or_meta_analysis","claimSupported":"Directly informs the Lanreotide evidence profile within the limits of its study design.","supportNature":"Direct or contextual support; no extrapolation beyond the source design.","qualification":"Publication identity verified; full-text risk-of-bias and applicability require governed review.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-automation-profile-corpus-v1","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1007/s11102-009-0169-z","sourceIdentityId":"ca5b0a1479437fc7eea47bab68ceb68e","sourceStatus":"active","sourceContentHash":"350e6c29212c91950e7e5e71b2b94ed02fe966920452daa71ed6a98d215db0a3","sourceVersion":1,"retrievedAt":"2026-09-09T22:20:33.332Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"pubmed:19189218","evidenceLane":"systematic_review","extractionPayload":{"outcomes":"No claim-level outcome imported without full-text adjudication.","limitations":"Source identity and relevance verified; detailed risk-of-bias and applicability remain for profile-level Owner review.","studyDesign":"systematic review","sourceStrength":{"grade":"A","score":86,"version":"WPF-ESR-1.0","dimensions":{"identity":100,"directness":85,"replication":70,"studyDesign":86,"regulatoryRelevance":60},"provisional":true},"populationOrModel":"See source abstract and full text; identity verified at PubMed."},"provenancePayload":{"doi":"10.1007/s11102-009-0169-z","locator":"https://pubmed.ncbi.nlm.nih.gov/19189218/","provider":"pubmed","sourceRole":"published_literature","retrievedAt":"2026-09-09T21:45:00Z","rawPayloadHash":"350e6c29212c91950e7e5e71b2b94ed02fe966920452daa71ed6a98d215db0a3","sourceRoleBasis":"provider_authoritative_index","providerRecordId":"19189218","rawPayloadReference":"pubmed:19189218"},"validationGates":{"gates":[{"id":"G1","passed":true,"required":true,"reasonCodes":[]},{"id":"G2","passed":true,"required":true,"reasonCodes":[]},{"id":"G3","passed":true,"required":true,"reasonCodes":[]},{"id":"G4","passed":true,"required":true,"reasonCodes":[]},{"id":"G5","passed":true,"required":true,"reasonCodes":[]},{"id":"G6","passed":true,"required":true,"reasonCodes":[]},{"id":"G7","passed":true,"required":true,"reasonCodes":[]},{"id":"G8","passed":true,"required":true,"reasonCodes":[]}],"sourceRole":"published_literature","disposition":"promote_internal","reasonCodes":[],"catastrophic":false,"ownerAuthorized":false,"sourceRoleBasis":"provider_authoritative_index","citationSourceType":"systematic_review_or_meta_analysis","admitsExactPublishedEvidence":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-09T22:20:33.332Z","updatedAt":"2026-09-09T22:31:57.546Z"},{"id":"53e5af6ab0724d1af4c5f418396f1be7","peptideId":"3008f1ff-3f15-452c-808d-b8223f27ee12","title":"Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/19646443/","evidenceTier":"phase_1_2","summary":"Therapy for polycystic liver is invasive, expensive, and has disappointing long-term results.","authors":"Loes van Keimpema, Frederik Nevens, Ragna Vanslembrouck, Martijn G H van Oijen, Aswin L Hoffmann, Helena M Dekker, Robert A de Man, Joost P H Drenth","publishingOrg":"Gastroenterology","publicationYear":2009,"doi":"10.1053/j.gastro.2009.07.052","pubmedId":"19646443","jurisdiction":null,"dateAccessed":"2026-09-09T22:20:33.332Z","editorialNotes":"Identity and metadata verified against the NCBI PubMed record; evidence strength is provisional pending Owner review.","sourceType":"peer_reviewed_research","claimSupported":"Directly informs the Lanreotide evidence profile within the limits of its study design.","supportNature":"Direct or contextual support; no extrapolation beyond the source design.","qualification":"Publication identity verified; full-text risk-of-bias and applicability require governed review.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-automation-profile-corpus-v1","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1053/j.gastro.2009.07.052","sourceIdentityId":"d9e294a0b1243686302cde1c51577b05","sourceStatus":"active","sourceContentHash":"d07e5fd079d18710869a3e4b907263fb5d476cd5be611fedf28f2bb86110fd35","sourceVersion":1,"retrievedAt":"2026-09-09T22:20:33.332Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"pubmed:19646443","evidenceLane":"human_interventional","extractionPayload":{"outcomes":"No claim-level outcome imported without full-text adjudication.","limitations":"Source identity and relevance verified; detailed risk-of-bias and applicability remain for profile-level Owner review.","studyDesign":"randomized or prospective clinical study","sourceStrength":{"grade":"B","score":80,"version":"WPF-ESR-1.0","dimensions":{"identity":100,"directness":85,"replication":70,"studyDesign":80,"regulatoryRelevance":60},"provisional":true},"populationOrModel":"See source abstract and full text; identity verified at PubMed."},"provenancePayload":{"doi":"10.1053/j.gastro.2009.07.052","locator":"https://pubmed.ncbi.nlm.nih.gov/19646443/","provider":"pubmed","sourceRole":"published_literature","retrievedAt":"2026-09-09T21:45:00Z","rawPayloadHash":"d07e5fd079d18710869a3e4b907263fb5d476cd5be611fedf28f2bb86110fd35","sourceRoleBasis":"provider_authoritative_index","providerRecordId":"19646443","rawPayloadReference":"pubmed:19646443"},"validationGates":{"gates":[{"id":"G1","passed":true,"required":true,"reasonCodes":[]},{"id":"G2","passed":true,"required":true,"reasonCodes":[]},{"id":"G3","passed":true,"required":true,"reasonCodes":[]},{"id":"G4","passed":true,"required":true,"reasonCodes":[]},{"id":"G5","passed":true,"required":true,"reasonCodes":[]},{"id":"G6","passed":true,"required":true,"reasonCodes":[]},{"id":"G7","passed":true,"required":true,"reasonCodes":[]},{"id":"G8","passed":true,"required":true,"reasonCodes":[]}],"sourceRole":"published_literature","disposition":"promote_internal","reasonCodes":[],"catastrophic":false,"ownerAuthorized":false,"sourceRoleBasis":"provider_authoritative_index","citationSourceType":"peer_reviewed_research","admitsExactPublishedEvidence":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-09T22:20:33.332Z","updatedAt":"2026-09-09T22:31:57.546Z"},{"id":"c9758598f5755c3621aa71c4afdbcc25","peptideId":"3008f1ff-3f15-452c-808d-b8223f27ee12","title":"Population pharmacokinetic analysis of lanreotide Autogel in healthy subjects : evidence for injection interval of up to 2 months.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/19071884/","evidenceTier":"phase_1_2","summary":"Lanreotide is a somatostatin analogue used for the treatment of acromegaly and neuroendocrine tumours.","authors":"Iñaki F Trocóniz, Josep-María Cendrós, Concepción Peraire, Joaquim Ramis, Maria J Garrido, Paolo F Boscani, Rosendo Obach","publishingOrg":"Clinical pharmacokinetics","publicationYear":2009,"doi":"10.2165/0003088-200948010-00004","pubmedId":"19071884","jurisdiction":null,"dateAccessed":"2026-09-09T22:20:33.332Z","editorialNotes":"Identity and metadata verified against the NCBI PubMed record; evidence strength is provisional pending Owner review.","sourceType":"peer_reviewed_research","claimSupported":"Directly informs the Lanreotide evidence profile within the limits of its study design.","supportNature":"Direct or contextual support; no extrapolation beyond the source design.","qualification":"Publication identity verified; full-text risk-of-bias and applicability require governed review.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-automation-profile-corpus-v1","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.2165/0003088-200948010-00004","sourceIdentityId":"dbaa2025ae557e6422b0caabd7e1d234","sourceStatus":"active","sourceContentHash":"ecd5f7415f6c0e590cf98dead127b5379917b9f338984299c19aed4529d1107c","sourceVersion":1,"retrievedAt":"2026-09-09T22:20:33.332Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"pubmed:19071884","evidenceLane":"human_interventional","extractionPayload":{"outcomes":"No claim-level outcome imported without full-text adjudication.","limitations":"Source identity and relevance verified; detailed risk-of-bias and applicability remain for profile-level Owner review.","studyDesign":"randomized or prospective clinical study","sourceStrength":{"grade":"B","score":80,"version":"WPF-ESR-1.0","dimensions":{"identity":100,"directness":85,"replication":70,"studyDesign":80,"regulatoryRelevance":60},"provisional":true},"populationOrModel":"See source abstract and full text; identity verified at PubMed."},"provenancePayload":{"doi":"10.2165/0003088-200948010-00004","locator":"https://pubmed.ncbi.nlm.nih.gov/19071884/","provider":"pubmed","sourceRole":"published_literature","retrievedAt":"2026-09-09T21:45:00Z","rawPayloadHash":"ecd5f7415f6c0e590cf98dead127b5379917b9f338984299c19aed4529d1107c","sourceRoleBasis":"provider_authoritative_index","providerRecordId":"19071884","rawPayloadReference":"pubmed:19071884"},"validationGates":{"gates":[{"id":"G1","passed":true,"required":true,"reasonCodes":[]},{"id":"G2","passed":true,"required":true,"reasonCodes":[]},{"id":"G3","passed":true,"required":true,"reasonCodes":[]},{"id":"G4","passed":true,"required":true,"reasonCodes":[]},{"id":"G5","passed":true,"required":true,"reasonCodes":[]},{"id":"G6","passed":true,"required":true,"reasonCodes":[]},{"id":"G7","passed":true,"required":true,"reasonCodes":[]},{"id":"G8","passed":true,"required":true,"reasonCodes":[]}],"sourceRole":"published_literature","disposition":"promote_internal","reasonCodes":[],"catastrophic":false,"ownerAuthorized":false,"sourceRoleBasis":"provider_authoritative_index","citationSourceType":"peer_reviewed_research","admitsExactPublishedEvidence":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-09T22:20:33.332Z","updatedAt":"2026-09-09T22:31:57.546Z"},{"id":"1c423557e9fe8579ecc954adf02ff08f","peptideId":"3008f1ff-3f15-452c-808d-b8223f27ee12","title":"Efficacy of lanreotide Autogel administered every 4-8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: a phase III trial.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/16918950/","evidenceTier":"phase_3","summary":"Depot somatostatin analogues are well accepted as either adjuvant or primary therapy for acromegaly, and their long dosage intervals facilitate adherence to treatment.","authors":"T Lucas, R Astorga, Spanish-Portuguese Multicentre Autogel Study Group on Acromegaly","publishingOrg":"Clinical endocrinology","publicationYear":2006,"doi":"10.1111/j.1365-2265.2006.02595.x","pubmedId":"16918950","jurisdiction":null,"dateAccessed":"2026-09-09T22:20:33.332Z","editorialNotes":"Identity and metadata verified against the NCBI PubMed record; evidence strength is provisional pending Owner review.","sourceType":"peer_reviewed_research","claimSupported":"Directly informs the Lanreotide evidence profile within the limits of its study design.","supportNature":"Direct or contextual support; no extrapolation beyond the source design.","qualification":"Publication identity verified; full-text risk-of-bias and applicability require governed review.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-automation-profile-corpus-v1","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1111/j.1365-2265.2006.02595.x","sourceIdentityId":"0af7add9ad0b2827980624fe21864c55","sourceStatus":"active","sourceContentHash":"f911f28b57d37413dbb5af60f619d0031dda22b6ea4563a7ae515cae6a507257","sourceVersion":1,"retrievedAt":"2026-09-09T22:20:33.332Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"pubmed:16918950","evidenceLane":"human_interventional","extractionPayload":{"outcomes":"No claim-level outcome imported without full-text adjudication.","limitations":"Source identity and relevance verified; detailed risk-of-bias and applicability remain for profile-level Owner review.","studyDesign":"randomized or prospective clinical study","sourceStrength":{"grade":"A","score":91,"version":"WPF-ESR-1.0","dimensions":{"identity":100,"directness":85,"replication":70,"studyDesign":91,"regulatoryRelevance":60},"provisional":true},"populationOrModel":"See source abstract and full text; identity verified at PubMed."},"provenancePayload":{"doi":"10.1111/j.1365-2265.2006.02595.x","locator":"https://pubmed.ncbi.nlm.nih.gov/16918950/","provider":"pubmed","sourceRole":"published_literature","retrievedAt":"2026-09-09T21:45:00Z","rawPayloadHash":"f911f28b57d37413dbb5af60f619d0031dda22b6ea4563a7ae515cae6a507257","sourceRoleBasis":"provider_authoritative_index","providerRecordId":"16918950","rawPayloadReference":"pubmed:16918950"},"validationGates":{"gates":[{"id":"G1","passed":true,"required":true,"reasonCodes":[]},{"id":"G2","passed":true,"required":true,"reasonCodes":[]},{"id":"G3","passed":true,"required":true,"reasonCodes":[]},{"id":"G4","passed":true,"required":true,"reasonCodes":[]},{"id":"G5","passed":true,"required":true,"reasonCodes":[]},{"id":"G6","passed":true,"required":true,"reasonCodes":[]},{"id":"G7","passed":true,"required":true,"reasonCodes":[]},{"id":"G8","passed":true,"required":true,"reasonCodes":[]}],"sourceRole":"published_literature","disposition":"promote_internal","reasonCodes":[],"catastrophic":false,"ownerAuthorized":false,"sourceRoleBasis":"provider_authoritative_index","citationSourceType":"peer_reviewed_research","admitsExactPublishedEvidence":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-09T22:20:33.332Z","updatedAt":"2026-09-09T22:31:57.546Z"},{"id":"524ec8c5896a4ceb3c09743a065b15a2","peptideId":"3008f1ff-3f15-452c-808d-b8223f27ee12","title":"Pharmacokinetics and population pharmacodynamic analysis of lanreotide Autogel.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/16154424/","evidenceTier":"phase_3","summary":"Somatostatin analogs are the first-line medical therapy for acromegaly, and the treatment of this disease has been simplified by the development of extended-release formulations of these analogs.","authors":"Joseph M Cendros, Concepción Peraire, Iñaki Fernández Trocóniz, Rossend Obach","publishingOrg":"Metabolism: clinical and experimental","publicationYear":2005,"doi":"10.1016/j.metabol.2005.04.014","pubmedId":"16154424","jurisdiction":null,"dateAccessed":"2026-09-09T22:20:33.332Z","editorialNotes":"Identity and metadata verified against the NCBI PubMed record; evidence strength is provisional pending Owner review.","sourceType":"peer_reviewed_research","claimSupported":"Directly informs the Lanreotide evidence profile within the limits of its study design.","supportNature":"Direct or contextual support; no extrapolation beyond the source design.","qualification":"Publication identity verified; full-text risk-of-bias and applicability require governed review.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-automation-profile-corpus-v1","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1016/j.metabol.2005.04.014","sourceIdentityId":"df31b30db1212caf1d35814cdfadc635","sourceStatus":"active","sourceContentHash":"e5d2f83f42cb3db745ad510f01ed151ad1de30093e69a46ffff511504e4e9dfb","sourceVersion":1,"retrievedAt":"2026-09-09T22:20:33.332Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"pubmed:16154424","evidenceLane":"human_interventional","extractionPayload":{"outcomes":"No claim-level outcome imported without full-text adjudication.","limitations":"Source identity and relevance verified; detailed risk-of-bias and applicability remain for profile-level Owner review.","studyDesign":"randomized or prospective clinical study","sourceStrength":{"grade":"A","score":91,"version":"WPF-ESR-1.0","dimensions":{"identity":100,"directness":85,"replication":70,"studyDesign":91,"regulatoryRelevance":60},"provisional":true},"populationOrModel":"See source abstract and full text; identity verified at PubMed."},"provenancePayload":{"doi":"10.1016/j.metabol.2005.04.014","locator":"https://pubmed.ncbi.nlm.nih.gov/16154424/","provider":"pubmed","sourceRole":"published_literature","retrievedAt":"2026-09-09T21:45:00Z","rawPayloadHash":"e5d2f83f42cb3db745ad510f01ed151ad1de30093e69a46ffff511504e4e9dfb","sourceRoleBasis":"provider_authoritative_index","providerRecordId":"16154424","rawPayloadReference":"pubmed:16154424"},"validationGates":{"gates":[{"id":"G1","passed":true,"required":true,"reasonCodes":[]},{"id":"G2","passed":true,"required":true,"reasonCodes":[]},{"id":"G3","passed":true,"required":true,"reasonCodes":[]},{"id":"G4","passed":true,"required":true,"reasonCodes":[]},{"id":"G5","passed":true,"required":true,"reasonCodes":[]},{"id":"G6","passed":true,"required":true,"reasonCodes":[]},{"id":"G7","passed":true,"required":true,"reasonCodes":[]},{"id":"G8","passed":true,"required":true,"reasonCodes":[]}],"sourceRole":"published_literature","disposition":"promote_internal","reasonCodes":[],"catastrophic":false,"ownerAuthorized":false,"sourceRoleBasis":"provider_authoritative_index","citationSourceType":"peer_reviewed_research","admitsExactPublishedEvidence":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-09T22:20:33.332Z","updatedAt":"2026-09-09T22:31:57.546Z"},{"id":"2737c2861e6ab5f4f5eaa0206892d91e","peptideId":"3008f1ff-3f15-452c-808d-b8223f27ee12","title":"Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/11788630/","evidenceTier":"phase_1_2","summary":"Lanreotide Autogel is a new long-acting aqueous preparation of lanreotide for the treatment of acromegaly and is administered by deep sc injection from a small volume, prefilled syringe.","authors":"Ph Caron, A Beckers, D R Cullen, M I Goth, B Gutt, P Laurberg, A M Pico, M Valimaki, W Zgliczynski","publishingOrg":"The Journal of clinical endocrinology and metabolism","publicationYear":2002,"doi":"10.1210/jcem.87.1.8153","pubmedId":"11788630","jurisdiction":null,"dateAccessed":"2026-09-09T22:20:33.332Z","editorialNotes":"Identity and metadata verified against the NCBI PubMed record; evidence strength is provisional pending Owner review.","sourceType":"peer_reviewed_research","claimSupported":"Directly informs the Lanreotide evidence profile within the limits of its study design.","supportNature":"Direct or contextual support; no extrapolation beyond the source design.","qualification":"Publication identity verified; full-text risk-of-bias and applicability require governed review.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-automation-profile-corpus-v1","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1210/jcem.87.1.8153","sourceIdentityId":"a1ba2ebc65980028eb4c810a4db176b6","sourceStatus":"active","sourceContentHash":"cf98db6d2ee5d6fc62f8b8766a07a5a0f9ec8dd2343ab1cefd858434f6e47347","sourceVersion":1,"retrievedAt":"2026-09-09T22:20:33.332Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"pubmed:11788630","evidenceLane":"human_interventional","extractionPayload":{"outcomes":"No claim-level outcome imported without full-text adjudication.","limitations":"Source identity and relevance verified; detailed risk-of-bias and applicability remain for profile-level Owner review.","studyDesign":"randomized or prospective clinical study","sourceStrength":{"grade":"B","score":80,"version":"WPF-ESR-1.0","dimensions":{"identity":100,"directness":85,"replication":70,"studyDesign":80,"regulatoryRelevance":60},"provisional":true},"populationOrModel":"See source abstract and full text; identity verified at PubMed."},"provenancePayload":{"doi":"10.1210/jcem.87.1.8153","locator":"https://pubmed.ncbi.nlm.nih.gov/11788630/","provider":"pubmed","sourceRole":"published_literature","retrievedAt":"2026-09-09T21:45:00Z","rawPayloadHash":"cf98db6d2ee5d6fc62f8b8766a07a5a0f9ec8dd2343ab1cefd858434f6e47347","sourceRoleBasis":"provider_authoritative_index","providerRecordId":"11788630","rawPayloadReference":"pubmed:11788630"},"validationGates":{"gates":[{"id":"G1","passed":true,"required":true,"reasonCodes":[]},{"id":"G2","passed":true,"required":true,"reasonCodes":[]},{"id":"G3","passed":true,"required":true,"reasonCodes":[]},{"id":"G4","passed":true,"required":true,"reasonCodes":[]},{"id":"G5","passed":true,"required":true,"reasonCodes":[]},{"id":"G6","passed":true,"required":true,"reasonCodes":[]},{"id":"G7","passed":true,"required":true,"reasonCodes":[]},{"id":"G8","passed":true,"required":true,"reasonCodes":[]}],"sourceRole":"published_literature","disposition":"promote_internal","reasonCodes":[],"catastrophic":false,"ownerAuthorized":false,"sourceRoleBasis":"provider_authoritative_index","citationSourceType":"peer_reviewed_research","admitsExactPublishedEvidence":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-09T22:20:33.332Z","updatedAt":"2026-09-09T22:31:57.546Z"},{"id":"f8e6f9014229e941c9d574278a17e118","peptideId":"3008f1ff-3f15-452c-808d-b8223f27ee12","title":"Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/11106918/","evidenceTier":"phase_1_2","summary":"The most effective option for the medical treatment of patients with acromegaly is the use of somatostatin analogues.","authors":"P Chanson, V Boerlin, C Ajzenberg, Y Bachelot, P Benito, J Bringer, P Caron, B Charbonnel, C Cortet, B Delemer, F Escobar-Jiménez, L Foubert","publishingOrg":"Clinical endocrinology","publicationYear":2000,"doi":"10.1046/j.1365-2265.2000.01134.x","pubmedId":"11106918","jurisdiction":null,"dateAccessed":"2026-09-09T22:20:33.332Z","editorialNotes":"Identity and metadata verified against the NCBI PubMed record; evidence strength is provisional pending Owner review.","sourceType":"peer_reviewed_research","claimSupported":"Directly informs the Lanreotide evidence profile within the limits of its study design.","supportNature":"Direct or contextual support; no extrapolation beyond the source design.","qualification":"Publication identity verified; full-text risk-of-bias and applicability require governed review.","verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-automation-profile-corpus-v1","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1046/j.1365-2265.2000.01134.x","sourceIdentityId":"e1cacc7b6cc5a55042f75ea8cd4272fc","sourceStatus":"active","sourceContentHash":"2e3e73bc80e3802677e26a79049c528550f212584715060072c6d96b20cd46de","sourceVersion":1,"retrievedAt":"2026-09-09T22:20:33.332Z","retrievalProvider":"NCBI PubMed","retrievalPayloadRef":"pubmed:11106918","evidenceLane":"human_interventional","extractionPayload":{"outcomes":"No claim-level outcome imported without full-text adjudication.","limitations":"Source identity and relevance verified; detailed risk-of-bias and applicability remain for profile-level Owner review.","studyDesign":"randomized or prospective clinical study","sourceStrength":{"grade":"B","score":80,"version":"WPF-ESR-1.0","dimensions":{"identity":100,"directness":85,"replication":70,"studyDesign":80,"regulatoryRelevance":60},"provisional":true},"populationOrModel":"See source abstract and full text; identity verified at PubMed."},"provenancePayload":{"doi":"10.1046/j.1365-2265.2000.01134.x","locator":"https://pubmed.ncbi.nlm.nih.gov/11106918/","provider":"pubmed","sourceRole":"published_literature","retrievedAt":"2026-09-09T21:45:00Z","rawPayloadHash":"2e3e73bc80e3802677e26a79049c528550f212584715060072c6d96b20cd46de","sourceRoleBasis":"provider_authoritative_index","providerRecordId":"11106918","rawPayloadReference":"pubmed:11106918"},"validationGates":{"gates":[{"id":"G1","passed":true,"required":true,"reasonCodes":[]},{"id":"G2","passed":true,"required":true,"reasonCodes":[]},{"id":"G3","passed":true,"required":true,"reasonCodes":[]},{"id":"G4","passed":true,"required":true,"reasonCodes":[]},{"id":"G5","passed":true,"required":true,"reasonCodes":[]},{"id":"G6","passed":true,"required":true,"reasonCodes":[]},{"id":"G7","passed":true,"required":true,"reasonCodes":[]},{"id":"G8","passed":true,"required":true,"reasonCodes":[]}],"sourceRole":"published_literature","disposition":"promote_internal","reasonCodes":[],"catastrophic":false,"ownerAuthorized":false,"sourceRoleBasis":"provider_authoritative_index","citationSourceType":"peer_reviewed_research","admitsExactPublishedEvidence":true},"engineState":"promoted_internal","engineRunId":null,"createdAt":"2026-09-09T22:20:33.332Z","updatedAt":"2026-09-09T22:31:57.546Z"}],"regulatory":[{"id":"9e141d1a3554bd38d1fce14756971005","peptideId":"3008f1ff-3f15-452c-808d-b8223f27ee12","jurisdiction":"United States (FDA — SOMATULINE DEPOT)","status":"approved","approvedIndication":"SOMATULINE DEPOT is FDA-approved for long-term treatment of acromegalic patients meeting label criteria, treatment of unresectable well- or moderately differentiated locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors to improve progression-free survival, and treatment of carcinoid syndrome to reduce short-acting somatostatin-analog rescue therapy.","rationale":"Authorization is product-, formulation-, dose-, population-, and indication-specific. The current label controls gallbladder, glucose, cardiovascular, thyroid, interaction, administration, and other safety requirements.","sourceTitle":"FDA Drugs@FDA — SOMATULINE DEPOT NDA 022074","sourceUrl":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022074","dateChecked":"2026-09-09T22:24:51.058Z","reviewDueAt":"2026-12-08T22:24:51.058Z","enteredById":null,"reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","publicationStatus":"published","factualObservationId":null,"createdAt":"2026-09-09T22:24:51.058Z","updatedAt":"2026-09-09T22:31:57.556Z"},{"id":"eb37ac0c326bee2035db69311664e680","peptideId":"3008f1ff-3f15-452c-808d-b8223f27ee12","jurisdiction":"United States (FDA — lanreotide acetate)","status":"approved","approvedIndication":"FDA application NDA 215395 covers a currently marketed lanreotide acetate injection product in the strengths and indications specified by its approved labeling.","rationale":"This is a separate product-level regulatory record, not an expansion of molecule-wide authorization. Product-specific labeling, delivery system, strengths, indications, and safety information control.","sourceTitle":"FDA Drugs@FDA — Lanreotide acetate NDA 215395","sourceUrl":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215395","dateChecked":"2026-09-09T22:24:51.058Z","reviewDueAt":"2026-12-08T22:24:51.058Z","enteredById":null,"reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","publicationStatus":"published","factualObservationId":null,"createdAt":"2026-09-09T22:24:51.058Z","updatedAt":"2026-09-09T22:31:57.556Z"}],"claims":[],"correctionHistory":[],"boundaries":{"observationsAreEvidence":false,"completionIsPublicationApproval":false,"medicalAdvice":false}}